“…In addition, a cohort study also stated that in the middle age group (41-50 and 51-60 years) of postmenopausal women, the Luminal B subtype (ER+, PR+/-, HER2-, Ki-67 14-30%) is the most diagnosed breast cancer in this group, while for the age group (61-70 and 71-80 years) most of the patients had the Luminal A subtype (ER+, PR+, HER2-, Ki-67 < 14%) [59]. It can be caused by the increase in fat tissue in the body, especially in postmenopausal women, causing an increase in the secretion of the hormone estrogen which results in an increased risk of invasive breast cancer with positive ER subtype [60][61][62]. Successful therapies for breast cancer, such as chemo-, radio-, and endocrine therapy are known to carry longterm side effects such as cardiotoxicity effects, peripheral neuropathy, arthralgia, muscle strength reduction, musculoskeletal pain, hot flushes, fatigue, depression, dyspareunia, thromboembolic event, and hypercholesterolemia [63][64][65][66][67].…”